𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A Randomized Phase II Study of Two Schedules of Bryostatin-1 (NSC339555) in Patients with Advanced Malignant Melanoma – A National Cancer Institute of Canada Clinical Trials Group Study

✍ Scribed by R.G. Tozer; S. Burdette-Radoux; K. Berlanger; M.L. Davis; R.C. Lohmann; J.R. Rusthoven; N. Wainman; B. Zee; L. Seymour

Book ID
110398431
Publisher
Springer US
Year
2002
Tongue
English
Weight
69 KB
Volume
20
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of trimetrexate in malign
Phase II study of trimetrexate in malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group Study
✍ Neill A. Iscoe; Elizabeth A. Eisenhauer; Audley J. Bodurtha 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 183 KB

The National Cancer Institute of Canada Clinical Trials Group carried out a phase II trial of trimetrexate given in a daily x 5 intravenous bolus schedule every 3 weeks in patients with measurable metastatic malignant melanoma who had not received previous chemotherapy. Significant hematologic toxic

Phase II study of flutamide in patients
Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study
✍ Daniele J. Perrault; Diane M. Logan; David J. Stewart; Vivien H. C. Bramwell; Al 📂 Article 📅 1988 🏛 Springer US 🌐 English ⚖ 271 KB

The National Cancer Institute of Canada (NCIC) Clinical Trials Group conducted a phase II study of the oral antiandrogen flutamide in 33 patients with metastatic breast cancer. Eight patients had received no prior systemic therapy for their metastatic disease and 13 had only one site of metastasis.